Hemab Therapeutics Holdings, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $24.2 million, or $0.80 per share, compared to a net loss of $12.2 million in the prior year period. The company holds $457.5 million in cash and marketable securities following its initial public offering completed in May 2026. Clinically, the FDA endorsed sutacimig data as sufficient for a Phase 3 pivotal trial in Glanzmann thrombasthenia, with initiation planned for the second half of 2026. The company also unveiled HMB-003, a novel antifibrinolytic program targeting heavy menstrual bleeding, and presented proof-of-mechanism data for HMB-002 in Von Willebrand Disease showing a ≥2.4-fold increase in VWF and Factor VIII. Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies to treat blood coagulation disorders.